bioRxiv · 10.1101/2020.09.01.278291
Tapping into a phospholipid-LRH-1 axis yields a powerful anti-inflammatory agent with in vivo activity against colitis
Abstract
Phospholipids are ligands for nuclear hormone receptors (NRs) and regulate transcriptional programs relevant to normal physiology and disease. Here, we demonstrate that mimicking phospholipid-NR interactions greatly improves agonists of liver receptor homolog-1 (LRH-1), a promising therapeutic target for diabetes and colitis. Conventional LRH-1 modulators partially occupy the binding pocket, leaving vacant a region important for phospholipid binding and allostery. Therefore, we constructed a set of hybrid molecules with elements of natural phospholipids appended to a synthetic LRH-1 agonist. The phospholipid-mimicking group improves binding affinity, increases LRH-1 transcriptional activity, promotes coregulator recruitment, and interacts with the targeted LRH-1 residues in crystal structures. The best new agonist markedly improves colonic histopathology and disease-related weight loss in a humanized LRH-1 murine T-cell transfer model of colitis. This is the first evidence of in vivo efficacy for an LRH-1 modulator in colitis, a leap forward in agonist development.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Mays, S. G., D'Agostino, E. H., Flynn, A. R., Huang, X., Wang, G., Liu, X., Millings, E. J., Okafor, C. D., Patel, A., Cato, M. L., Cornelison, J. L., Melchers, D., Houtman, R., Moore, D. D., Calvert, J. W., Jui, N. T., Ortlund, E. A.. 2020-09-01. Tapping into a phospholipid-LRH-1 axis yields a powerful anti-inflammatory agent with in vivo activity against colitis. https://doi.org/10.1101/2020.09.01.278291
Cite the original work for its findings. Save a collection to share your selection of sources.